A Phase 2, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of JKB-122 in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis
Latest Information Update: 04 Jan 2024
At a glance
- Drugs JKB 122 (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors TaiwanJ Pharmaceuticals
Most Recent Events
- 11 Feb 2020 New trial record